Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy

Oncologist

Volumn 12, Issue 2, 2007, Pages 231-242

  Henry, David H ^a   Dahl, Naomi V ^b   Auerbach, Michael ^c   Tchekmedyian, Simon ^d   Laufmane, Leslie R ^e  

^a PENNSYLVANIA HOSPITAL   (United States)

^b Watson Laboratories Inc   (United States)

^c Auerbach Hematology/Oncology   (United States)

^d Pacific Shores Medical Group   (United States)

^e Hematology/Oncology Consultants Inc   (United States)

Author keywords

Anemia; Cancer; Chemotherapy; Epoetin alfa; Iron

Indexed keywords

FERRIC GLUCONATE; FERRITIN; FERROUS SULFATE; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANGINA PECTORIS; ANOREXIA; ARTICLE; ASTHENIA; BACKACHE; BLOOD; CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; HYPOTENSION; INJECTION SITE PAIN; IRON THERAPY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MELENA; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TASTE DISORDER; TINNITUS; TREATMENT OUTCOME; TREMOR; VASODILATATION; VOMITING;

ADMINISTRATION, ORAL; AGED; ANEMIA; ANTINEOPLASTIC AGENTS; EPOETIN ALFA; FEMALE; FERRIC COMPOUNDS; HEMATINICS; HUMANS; IRON; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES;

EID: 33847046008     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-2-231     Document Type: Article

References (29)

1. Henry DH. Supplemental iron: A key to optimizing the response of cancer-related anemia to rHuEPO? The Oncologist 1998;3:275-278.
2. Demetri GD, Kris M, Wade J et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. J Clin Oncol 1998;16:3412-3425.
3. Gabrilove JL, Cleeland CS, Livingston RB et al. Clinical evaluation of once weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-2882.
4. Glaspy J, Bukowski R, Steinberg D et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997;15:1218-1234.
5. Littlewood TJ, Bajetta E, Nortier JW et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
6. Macdougall IC. Strategies for iron supplementation: Oral versus intravenous. Kidney Int 1999;69:S61-S66.
7. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Hemodialysis Adequacy: Update 2000. Am J Kidney Dis 2001;37:S7-S64.
8. Auerbach M, Ballard H, Trout JR et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial. J Clin Oncol 2004;22:1301-1307.
9. Ferrlecit (sodium ferric gluconate complex in sucrose injection) [package insert]. Corona, CA: Watson Pharmaceuticals, Inc.; 2004.
10. Michael B, Coyne DW, Folkert VW et al. Sodium ferric gluconate complex in haemodialysis patients: A prospective evaluation of long-term safety. Nephrol Dial Transplant 2004;19:1576-1580.
11. Nissenson AR, Lindsay RM, Swan S et al. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial. Am J Kidney Dis 1999;33:471- 482.
12. Ludwig H, Van Belle S, Barrett-Lee P et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-2306.
13. Cazzola M, Mercuriali F, Brugnara C. Use of recombinant human erythropoietin outside the setting of uremia. Blood 1997;89:4248-4267.
14. Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood 2000;96:823-833.
15. Thomas C, Thomas L. Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 2002;48:1066-1076.
16. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995;26:41-46.
17. Macdougall IC, Tucker B, Thompson J et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996;50:1695-1699.
18. Markowitz GS, Kahn GA, Feingold RE et al. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin Nephrol 1997;48:34-40.
19. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011-1023.
20. Lalle M, Pistillucci G, AntimiMet al. Epoetin alfa 4000 U once weekly and intravenous iron supply in solid tumor patients: Early increase of hemoglobin level during chemotherapy. J Exp Clin Cancer Res 2005;24:197-201.
21. Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextran. Am J Kidney Dis 1999;33:464-470.
22. Coyne DW, Adkinson NF, Nissenson AR et al. Sodium ferric gluconate complex in hemodialysis patients. II: Adverse reactions in iron-dextran- sensitive and dextran-tolerant patients. Kidney Int 2003;63:217-224.
23. Michael B, Coyne DW, Fishbane S et al. Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran. Kidney Int 2002;61:1830-1839.
24. Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterol 2004;127:S79-S86.
25. Besarab A, Frinak S, Yee J. An indistinct balance: The safety and efficacy of parenteral iron therapy. J Am Soc Nephrol 1999;10:2029-2043.
26. Hoen B. Iron and infection: Clinical experience. Am J Kidney Dis 1999;34:S30-S34.
27. Kalantar-Zadeh K, Regidor DL, McAllister CJ et al. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005;16:3070-3080.
28. Rodgers GM 3rd, Cella D, Chanan-Khan A et al. Cancer- and treatment-related anemia. J Natl Compr Canc Netw 2005 3:772-789.
29. 12 deficiency in anemic cancer patients prior to erythropoiesis- stimulating agent therapy. Community Oncol (in press).